Last update 01 Nov 2024
ActualEyes, Inc.

ActualEyes, Inc.

Holding Company|
2018|
Kyoto-fu, Japan
|
10-50
|
www.actualeyes.co.jp

Overview

Tags

Eye Diseases
Congenital Disorders
Other Diseases
Cell therapy
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease1
Immune System Diseases1
Nervous System Diseases1
Hemic and Lymphatic Diseases1
Infectious Diseases1
Neoplasms1
Top 5 Drug TypeCount
Cell therapy2
Unknown1
Small molecule drug1
Top 5 TargetCount
mTOR(Serine/threonine-protein kinase mTOR)1
ROCK(Rho-associated kinases)1

Related

4
Drugs associated with ActualEyes, Inc.
Sirolimus
Target
mTOR
Mechanism
mTOR inhibitors
Active Org.
Santen Pharmaceutical Co., Ltd.Santen Pharmaceutical Co., Ltd. [+23]
Originator Org.
Pfizer Inc.Pfizer Inc.
Active Indication
Vascular Malformations [+79]
Inactive Indication
Acute Erythroblastic Leukemia [+118]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date15 Sep 1999
AE-101
Target
ROCK
Mechanism
ROCK inhibitors
Active Org.
ActualEyes, Inc.ActualEyes, Inc.
Originator Org.
ActualEyes, Inc.ActualEyes, Inc.
Active Indication
Corneal endotheliolitis [+1]
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
DWR-2206
Target-
Mechanism-
Active Org.
ActualEyes, Inc.ActualEyes, Inc. [+1]
Originator Org.
D. Western Therapeutics Institute, Inc.D. Western Therapeutics Institute, Inc.
Active Indication
Bullous keratopathy
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with ActualEyes, Inc.
NCT05376176 / Active, not recruitingPhase 2
A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) - PHANTOM Study
100 Clinical Results associated with ActualEyes, Inc.
Login to view more data
0 Patents (Medical) associated with ActualEyes, Inc.
Login to view more data
100 Deals associated with ActualEyes, Inc.
Login to view more data
100 Translational Medicine associated with ActualEyes, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
3
1
Phase 2 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Sirolimus
 ( mTOR )		Fuchs' Endothelial Dystrophy
More
Phase 2
AE-101
 ( ROCK )		Fuchs' Endothelial Dystrophy
More
Preclinical
AE-002
Fuchs' Endothelial Dystrophy
More
Preclinical
DWR-2206
Bullous keratopathy
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free